Share capital and share based payments - Disclosure of Number and Weighted Average Exercise Prices of Other Equity Instruments (Details)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12 Months Ended |
|
Jul. 25, 2025
shares
|
May 07, 2025
shares
|
Nov. 13, 2024
shares
|
Aug. 01, 2024
shares
|
Jun. 10, 2024
shares
|
Feb. 15, 2024
shares
|
Dec. 31, 2023
shares
employee
€ / shares
|
Dec. 21, 2023
shares
|
Apr. 14, 2023
shares
|
Dec. 16, 2022
shares
|
Dec. 12, 2022
shares
|
Oct. 03, 2022
shares
|
Feb. 14, 2022
shares
|
Oct. 01, 2021
shares
|
Jul. 22, 2021
shares
|
Aug. 05, 2020
shares
|
Jul. 03, 2019
shares
|
Apr. 29, 2019
shares
|
Jan. 14, 2019
shares
|
Apr. 03, 2018
shares
|
Sep. 20, 2017
shares
|
Dec. 30, 2016
shares
|
Oct. 21, 2016
shares
|
Jul. 01, 2015
shares
|
Apr. 27, 2015
shares
|
Jul. 16, 2014
shares
|
Jul. 17, 2013
shares
|
Dec. 31, 2025
shares
€ / shares
|
Dec. 31, 2024
shares
€ / shares
|
Dec. 31, 2023
shares
€ / shares
|
| Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16,173,374
|
15,872,874
|
12,820,670
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,448,557
|
3,632,005
|
3,057,735
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,890,199
|
4,368,529
|
3,271,690
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
6,491,245
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,834,618
|
7,872,340
|
6,491,245
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
7,242,172
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,561,680
|
8,621,332
|
7,242,172
|
| BSAAR 2011 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
650,000
|
650,000
|
650,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
25,000
|
25,000
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
625,000
|
625,000
|
625,000
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 2.04
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 2.04
|
€ 2.04
|
€ 2.04
|
| BSAAR 2012 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
146,050
|
146,050
|
146,050
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,250
|
12,250
|
12,250
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
133,800
|
133,800
|
133,800
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 2.04
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 2.04
|
€ 2.04
|
€ 2.04
|
| BSAAR 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,050,382
|
|
|
|
1,050,382
|
1,050,382
|
1,050,382
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,048,442
|
2,720
|
2,720
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,940
|
1,940
|
1,940
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
1,045,722
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
1,045,722
|
1,045,722
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
1,045,722
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
1,045,722
|
1,045,722
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 7.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 7.20
|
€ 7.20
|
€ 7.20
|
| AGAP Management 2016-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,000
|
|
|
|
|
2,000
|
2,000
|
2,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
550
|
550
|
550
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
250
|
250
|
250
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
1,200
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,200
|
1,200
|
1,200
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
156,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
156,000
|
156,000
|
156,000
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGAP Employees 2016-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,486
|
|
|
|
|
2,486
|
2,486
|
2,486
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
251
|
251
|
251
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
357
|
187
|
172
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
2,063
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,878
|
2,048
|
2,063
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
268,190
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
244,140
|
266,240
|
268,190
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA Management 2016-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
|
|
|
|
50,000
|
50,000
|
50,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
50,000
|
50,000
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGAP Management 2016-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,000
|
|
|
|
|
3,000
|
3,000
|
3,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
3,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,000
|
3,000
|
3,000
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
333,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
333,000
|
333,000
|
333,000
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA Management 2016-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
250,000
|
|
|
|
|
|
250,000
|
250,000
|
250,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
250,000
|
250,000
|
250,000
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGAP Employees 2017-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,725
|
5,725
|
5,725
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,725
|
5,725
|
5,725
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGAP Management 2017-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,400
|
2,400
|
2,400
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,400
|
2,400
|
2,400
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA Employee 2017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28,556
|
|
|
|
|
|
|
|
114,500
|
114,500
|
114,500
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,000
|
4,000
|
4,000
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
110,500
|
110,500
|
110,500
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA Bonus 2018-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
90,650
|
|
|
|
|
|
|
|
|
67,028
|
67,028
|
67,028
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
469
|
469
|
469
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
66,559
|
66,559
|
66,559
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGAP Perf Employees 2018-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
327,500
|
327,500
|
327,500
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
224,375
|
224,375
|
224,375
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
103,125
|
103,125
|
103,125
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGAP Perf Management 2018-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
260,000
|
260,000
|
260,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
150,000
|
150,000
|
150,000
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
110,000
|
110,000
|
110,000
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA Employees 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
90,650
|
90,650
|
90,650
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000
|
5,000
|
5,000
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
85,650
|
85,650
|
85,650
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA New Members 2017-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
|
|
|
|
|
|
|
|
|
25,000
|
25,000
|
25,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
25,000
|
25,000
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA Bonus 2019-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
57,376
|
|
|
|
|
|
|
|
|
|
|
57,376
|
57,376
|
57,376
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
57,376
|
57,376
|
57,376
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGAP 2019 Employees 2019 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
546,700
|
546,700
|
546,700
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
375,150
|
375,150
|
375,150
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
171,550
|
171,550
|
171,550
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGAP 2019 Management 2019 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
355,000
|
355,000
|
355,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
207,500
|
207,500
|
207,500
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
147,500
|
147,500
|
147,500
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA Bonus 2020-1 & 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
79,861
|
79,861
|
79,861
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17,885
|
17,885
|
17,885
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
61,976
|
61,976
|
61,976
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA Perf Employees 2020-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
769,202
|
|
|
|
|
|
|
|
|
|
|
|
766,650
|
766,650
|
766,650
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
681,420
|
681,420
|
681,420
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
85,230
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
85,230
|
85,230
|
85,230
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA Perf Management 2020-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
710,000
|
|
|
|
|
|
|
|
|
|
|
|
710,000
|
710,000
|
710,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
580,000
|
580,000
|
580,000
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
130,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
130,000
|
130,000
|
130,000
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA Bonus 2021-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
125,748
|
|
|
|
|
|
|
|
|
|
|
|
|
125,748
|
125,748
|
125,748
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
125,748
|
125,748
|
125,748
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA Perf Employees 2021-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
1,066,600
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,066,600
|
1,066,600
|
1,066,600
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
454,520
|
454,520
|
247,300
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
612,080
|
612,080
|
0
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
819,300
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
819,300
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
819,300
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
819,300
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA Perf Management 2021-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
610,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
610,000
|
610,000
|
610,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
194,000
|
194,000
|
130,000
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
416,000
|
416,000
|
0
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
480,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
480,000
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
480,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
480,000
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA "Plan Epargne Entreprise" 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
138,960
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
138,960
|
138,960
|
138,960
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
138,960
|
138,960
|
138,960
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA Bonus 2022-1 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
128,061
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
128,061
|
128,061
|
128,061
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
128,061
|
128,061
|
128,061
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA Perf Employees 2022-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
1,371,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,371,500
|
1,371,500
|
1,371,500
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
400,000
|
299,000
|
198,000
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
971,500
|
0
|
0
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
1,173,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
1,072,500
|
1,173,500
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
1,173,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
1,072,500
|
1,173,500
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA Perf Management 2022-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
550,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
550,000
|
550,000
|
550,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
550,000
|
0
|
0
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
550,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
550,000
|
550,000
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
550,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
550,000
|
550,000
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA "Plan Epargne Entreprise" 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
163,293
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
163,293
|
163,293
|
163,293
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
163,293
|
163,293
|
163,293
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA New Members 2023-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
25,000
|
25,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
25,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
25,000
|
25,000
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
25,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
25,000
|
25,000
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA Perf Employees 2023-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
1,403,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,403,500
|
1,403,500
|
1,403,500
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
508,500
|
129,750
|
4,500
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
1,399,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
895,000
|
1,273,750
|
1,399,000
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
1,399,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
895,000
|
1,273,750
|
1,399,000
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA Perf Management 2023-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
750,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
750,000
|
750,000
|
750,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
225,000
|
0
|
0
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
750,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
525,000
|
750,000
|
750,000
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
750,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
525,000
|
750,000
|
750,000
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| AGA New Members 2024-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
25,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
25,000
|
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
0
|
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
25,000
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
25,000
|
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
|
| AGA "Plan Epargne Entreprise" 2024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
68,744
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
68,744
|
68,744
|
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
68,744
|
68,744
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
|
| AGA Perf Management 2024-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
150,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
150,000
|
150,000
|
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
150,000
|
150,000
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
150,000
|
150,000
|
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
|
| AGA employees 2024-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
370,560
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
370,560
|
370,560
|
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
93,480
|
1,800
|
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
277,080
|
368,760
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
277,080
|
368,760
|
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
|
| AGA Perf Employees 2024-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
1,162,900
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,162,900
|
1,162,900
|
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
304,000
|
0
|
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
858,900
|
1,162,900
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
858,900
|
1,162,900
|
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
|
| AGA Perf Management 2024-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
975,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
975,000
|
975,000
|
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
375,000
|
0
|
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
600,000
|
975,000
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
600,000
|
975,000
|
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
|
| AGA Management 2024-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000
|
200,000
|
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000
|
200,000
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000
|
200,000
|
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
|
| AGA employees 2025-01 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
220,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
220,500
|
|
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
56,200
|
|
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
164,300
|
|
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
|
|
| Stock Options 2020-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
102,000
|
102,000
|
102,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
102,000
|
102,000
|
102,000
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
€ 0
|
€ 0
|
| Stock Options 2024-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000
|
100,000
|
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000
|
0
|
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
100,000
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
100,000
|
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 2.18
|
€ 2.18
|
|
| BSA 2011-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
225,000
|
225,000
|
225,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
25,000
|
25,000
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000
|
200,000
|
200,000
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 1.77
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 1.77
|
€ 1.77
|
€ 1.77
|
| BSA 2013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
237,500
|
237,500
|
237,500
|
237,500
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,500
|
12,500
|
12,500
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
225,000
|
225,000
|
225,000
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 2.36
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 2.36
|
€ 2.36
|
€ 2.36
|
| BSA 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
150,000
|
|
150,000
|
150,000
|
150,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
75,000
|
75,000
|
0
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
75,000
|
75,000
|
75,000
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
75,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
75,000
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
75,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
75,000
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 8.65
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 8.65
|
€ 8.65
|
€ 8.65
|
| BSA 2015-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
70,000
|
|
|
70,000
|
70,000
|
70,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
70,000
|
0
|
0
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
70,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
70,000
|
70,000
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
70,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
70,000
|
70,000
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 9.59
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 9.59
|
€ 9.59
|
€ 9.59
|
| BSA 2015-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,200
|
|
|
|
14,200
|
14,200
|
14,200
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,200
|
0
|
0
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
14,200
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
14,200
|
14,200
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
14,200
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
14,200
|
14,200
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 14.05
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 14.05
|
€ 14.05
|
€ 14.05
|
| BSA 2017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37,000
|
|
|
|
|
|
|
37,000
|
37,000
|
37,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
37,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37,000
|
37,000
|
37,000
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
37,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37,000
|
37,000
|
37,000
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 11.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 11.00
|
€ 11.00
|
€ 11.00
|
| BSA 2022-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
40,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
40,000
|
40,000
|
40,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31,740
|
31,740
|
31,740
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
8,260
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,260
|
8,260
|
8,260
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
8,260
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,260
|
8,260
|
8,260
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 2.31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 2.31
|
€ 2.31
|
€ 2.31
|
| BSA 2023-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
50,000
|
50,000
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,000
|
12,000
|
12,000
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
38,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
38,000
|
38,000
|
38,000
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
38,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
38,000
|
38,000
|
38,000
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 2.26
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 2.26
|
€ 2.26
|
€ 2.26
|
| BSA-2025-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
80,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80,000
|
|
|
| Number of other equity instruments forfeited in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30,000
|
|
|
| Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
0
|
0
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
0
|
0
|
| Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 1.62
|
|
|